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Summary
Objective: To explore reasons for discrepant results between systematic reviews (SR)/meta-analyses (MA) of the efﬁcacy and safety of
hyaluronic acid/hyaluronan/hylan (HA) therapy in the treatment of osteoarthritis (OA) of the knee.
Methods: A decision algorithm was utilised to identify reasons for discordance among six SR. Sources of discordance such as clinical ques-
tion, trial selection and inclusion, data extraction, assessment of study quality, assessment of the ability to combine trials, and statistical
methods for data synthesis were examined.
Results: A similar question was asked in all six SR. Different trials were selected for inclusion in the reviews mainly because of differences in
the search strategies and selection criteria. Although similar methods for data extraction were utilised, differences were found both in the out-
come measures and time-points selected for extraction. Methodological quality was not always formally assessed. Different statistical
methods for data synthesis resulted in conﬂicting estimates of therapeutic effect.
Conclusions: Reasons for the inconsistency of results reported in the six SR were identiﬁed. Using the principles of the GRADE approach for
estimating the therapuetic effect of HA in the treatment of OA of the knee, there is moderate evidence suggesting that further research is un-
likely to change our conﬁdence in the estimate of the effect. In the balance of beneﬁt to harm, the trade-off is probable beneﬁt with respect to
pain reduction and physical function improvement with low risk of harm.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Level I evidence from systematic reviews (SR) is widely
regarded as high level evidence likely to inﬂuence evi-
dence-based decision-making in routine clinical care1. SR
synthesize the results of all relevant studies by using strat-
egies that limit bias and random error2. As the number of
SR addressing the same therapeutic question increases,
the possibility for conﬂict among reviews increases. The ex-
tent to which different methodological approaches and ana-
lytic strategies may inﬂuence the outcome of meta-analyses
in SR has been previously reported3. The authors proposed
a decision algorithm to help decision-makers understand
discordance among reviews3. This algorithm has been uti-
lised to explore reasons for discrepant results of SR in com-
plementary medicine and in Helicobacter pylori eradication
therapy in non-ulcer dyspepsia4,5.
The current debate over the efﬁcacy and safety of HA in
the treatment in knee OA has not been resolved by the pub-
lication of several discordant SR. Six SR have been pub-
lished within the last four years with differing conclusions
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Received 18 August 2006; revision accepted 28 January 2007.1(Table I)6e11. Although other SR and critical appraisals of
HA have been reported, these were not assessed in this
publication because they did not include a meta-analysis.
We compared the methodology used in the six SR and
examined potential explanations for discordance in order
to compare the strength of the evidence for the therapeutic
efﬁcacy of HA compared to placebo in the treatment of OA
of the knee.
Method
The decision algorithm proposed by Jadad et al. to help
decision-makers select between discordant reviews was
applied to six reported SR3. Potential sources of discor-
dance identiﬁed to be examined were: the clinical question,
study selection and inclusion, data extraction, assessment
of study quality, assessment of the ability to combine stud-
ies, and the statistical methods for data synthesis. In order
to grade the quality of the evidence and make a recommen-
dation about the therapeutic effect of HA compared to
placebo in the treatment of knee OA, the four elements of
the GRADE (Grades of Recommendation Assessment, De-
velopment and Evaluation) system, study design, study
quality (high, moderate, low, very low), consistency, and di-
rectness were assessed to answer the question, ‘‘Should
HA be used for the treatment of knee OA?’’12.424
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The ﬁrst step in the algorithm is to determine if the
reviews asked the same clinical question. It appears that
all six reviews asked a similar question (Table II). Since
the reviews addressed the same question, the next step
was to establish whether the reviews included the same pri-
mary trials13e63 (Table III). One of the 47 trials was common
to all six reviews: Huskisson 199936. Nine trials were com-
mon to ﬁve reviews: Altman 199814, St. J. Dixon 198858,
Dougados 199327, Henderson 199434, Lohmander 199646,
Petrella 200249, Puhl 199352, Scale 199454, and Wobig
199861. Six trials were common to four reviews: Brandt
200117, Carrabba 199519, Grecomoro 198730, La Sala
199528, Tamir 200159, and Wu 199763. Arrich et al. identi-
ﬁed 24 randomized controlled trials (RCT) and completed
analyses on 22 RCT (excluding Lohmander 199646 and
Scale 199454)6. Bellamy et al. identiﬁed 76 RCT of which
40 were placebo-controlled trials7. Although these re-
viewers reported results by single HA product, a class-
based analysis was completed in which 22 RCT for the
pain on weight-bearing outcome measure were included.
Lo et al. identiﬁed 22 RCT and completed an intention-to-
treat meta-analysis on seven RCT (Carrabba 199519,
Creamer 199422, Dahlberg 199424, Jubb 200340, La Sala
199528, Pham 200350, and Wobig 199861)8. Medina et al.
identiﬁed 35 potentially eligible studies and selected seven
Table I
What were the results of the six reviews?
Arrich
et al.6
‘‘According to the currently available evidence,
intra-articular HA has not been proven clinically
effective and may be associated with a greater
risk of adverse events.’’ WMD -3.8, -4.3, -7.1
and -0.5 for pain during movement from
2-6, 10-14, 22-30 and 44-60 weeks, respectively.
Bellamy
et al.7
‘‘The analyses support the contention that the
HA class of products is superior to placebo.
There is considerable between-product, between-
variable and time-dependent variability in the clinical
response. .within the constraints of the trial
designs employed, no major safety issues were
detected. Overall, the.analyses support the use
of the HA class of products in the treatment of knee
OA.’’ WMD -8, -13, -9 and -3 for pain on weight
bearing from 1-4, 5-13, 14-26 and 45-52 weeks,
respectively.
Lo et al.8 ‘‘Intra-articular HA has a small effect when
compared with an intra-articular placbo. The
presence of publication bias suggests even this
effect may be overestimated.’’ Pooled effect size 0.32
(¼ nonsteroidal anti-inﬂammatory drugs over
acetaminophen).
Medina
et al.9
‘‘HA injection may provide short-term relief of pain
and improved functionality for patients with OA of
the knee, but beneﬁts do not last beyond 6 months.’’
Modawal
et al.10
‘‘Intra-articular viscosupplementation was
moderately effective in relieving knee pain in
patients with OA at 5 to 7 and 8 to 10 weeks after
the last injection but not at 15 to 22 weeks.’’ WMD 4.4,
17.7, 18.1 and 4.4 for pain VAS from 1, 5-7, 8-12 and
15-22 weeks, respectively.
Wang
et al.11
‘‘This meta-analysis conﬁrmed the therapeutic
efﬁcacy and safety of intra-articular injection
of HA for the treatment of OA of the knee.’’
Adjusted sum of the pain intensity differences
percentage 13.4.
WMD:weightedmean difference; HA: hyaluronic acid/hylaluronan/
hylan; OA: osteoarthritis.for inclusion in their meta-analysis (Altman 200415, Day
200425, Dougados 199327, Huskisson 199936, Karlsson
200241, Petrella 200249, and Pham 200451).9 Modawal
et al. identiﬁed 17 RCT and completed analysis on nine
RCT (Altman 199814, Grecomoro 198730, Henderson
199434, Huskisson 199936, Lohmander 199646, Petrella
200249, Puhl 199352, Scale 199454, and Wobig 199861)10.
Wang et al. identiﬁed 25 RCT and analysed 20 (excluding
abstracts which did not provide quantitative data: Isdale
199337, Jubb 200139, Karlsson 199941, Moreland 199347,
and Russell 199253)11.
Differences were detected due to different strategies to
search the literature, different criteria for selecting trials for
inclusion (for example, publication status and language
of publication), and application of the selection criteria
(Table IV). Different electronic databases were searched
to identify trials. Search dates varied but this was mainly at-
tributable to publication dates of the reviews. Hand-search-
ing of specialized journals, journal supplements, and
proceedings of conferences was utilised in four of the re-
views7,8,10,11; and of reference lists of retrieved studies in
the Medina et al. review9, while not utilised in the Arrich
et al. review6. Some review authors attempted to contact
authors of trials or industry for unpublished data and/or
manuscripts. Three review groups restricted trials to those
published only in the English language9-11. Bellamy et al. in-
cluded seven published RCT which were not included in
any of the other reviews7: Cubukcu 200523, Kotevoglu
200643, Neustadt 200548, Sezgin 200555, Shichikawa
198356, Shichikawa1983a57, and Wobig 199962. The Shi-
chikawa trials were originally published in Japanese but
an English translation was available. Abstracts were in-
cluded in three reviews7,8,11 but not in the other three6,9,10.
Bellamy et al. included three abstracts (Groppa 200132, Gu-
ler 199633, and Tsai 200360) that were not included in any of
the other ﬁve reviews7. Unpublished manuscripts and data
from unpublished manuscripts were included in some re-
views but not in others. Arrich et al.6 included an unpub-
lished article from Russell 199253. It was classiﬁed as
a high quality trial (i.e. reported blinding, allocation conceal-
ment and intention-to-treat analysis). Bellamy et al. included
three unpublished manuscripts (Hizmetli 199935, Lin
200445, and Moreland 199347) the ﬁrst two which had
been submitted for publication7. Lo et al. received data for
Table II
Do the reviews ask the same question?
Arrich et al.6 ‘‘We performed a systematic review and
meta-analysis of randomized controlled
trials to assess the effectiveness of
intra-articular HA for the treatment of OA
of the knee.’’
Bellamy et al.7 ‘‘To assess the effects of viscosupplementation
in the treatment of OA of the knee.’’
Lo et al.8 ‘‘To evaluate whether intra-articular HA is
efﬁcacious in treating knee OA.’’
Medina et al.9 ‘‘Should your patient opt for HA injection?’’
Modawal
et al.10
‘‘To evaluate the efﬁcacy of intra-articular
viscosupplementation therapy with HA for pain
relief of knee OA, we conducted a meta-analysis
of randomized, double-blind, placebo-controlled
trials.’’
Wang et al.11 ‘‘To elucidate the therapeutic efﬁcacy and safety
of intra-articular injection of HA in the treatment
of OA of the knee by conducting a meta-analysis
of randomized controlled trials.’’
HA: hyaluronic acid; OA: osteoarthritis.
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Do the reviews include the same trials?
Trial (Year) Arrich 20056 Bellamy 20067 Lo 20038 Medina 20069 Modawal 200510 Wang 200411
Adams 199513     þz 
Altman 199814 þ þy þ R þy þ
Altman 200415  þ  þy  
Bragantini 198716 þ þy    þ
Brandt 200117 þ þ þ R  þ
Bunyaratavej 200118 þ þ  R  
Carrabba 199519 þ þy þy   þ
Cohen 1994 [abstract]20  þ þ   þ
Corrado 199521 þ þy þ   þ
Creamer 199422  þy þy R  þ
Cubukcu 200523  þy    
Dahlberg 199424 þ  þy   
Day 200425 þ þ  þy  
Dickson 200126  þ  R  þ
Dixon 1988¼St. J. Dixon 198858 þ þy þ R þz þ
Dougados 199327 þ þy þ þy þz þ
Graf 199329     þz 
Grecomoro 198730 þ þy   þy þ
Grecomoro 199231     þz 
Groppa 2001 [abstract]32  þ    
Guler 1996 [abstract]333  þ    
Henderson 199434 þ þy þ R þy þ
Hizmetli 199935[unpublished
manuscript]
 þ    
Huskisson 199936 þ þy þ þy þy þ
Isdale 1993 [abstract]37      þ*
Jones 199538     þz 
Jubb 2001 [abstract]39      þ*
Jubb 200340 þ þy þy R  
Karlsson 1999 [abstract]41      þ*
Karlsson 200242 þ þy þ þy  
Kotevoglu 200643  þ    
La Sala 199528¼ Formiguera
Sala 1995
þ þ þy   þ
Leardini 199144     þz 
Lin (see Tsai 2003)45
[unpublished manuscript]
 þy (count as Tsai)    
Lohmander 199646 þ* þy þ R þy þ
Moreland 1993 [abstract]47
[unpublished manuscript]
 þy    þ*
Neustadt 200548  þ    
Petrella 200249 þ þy þ þy þy 
Pham 2003 [abstract]50
Pham 200451
 þ þy þy  
Puhl 199352 þ þy þ R þy þ
Russell 1992 [abstract]53
[unpublished manuscript]
þ  þ   þ*
Scale 1994a54 þ* þhy þ  þy þ
Sezgin 200555  þ    
Shichikawa 198356  þ    
Shichikawa 1983a57  þ    
Tamir 200159 þ þ þ R  þ
Tsai 2003 [abstract]60¼ Lin
[unpublished manuscript]
 þy    
Wobig 199861 þ þy þy R þy þ
Wobig 199962  þy    
Wu 199763 þ þ  R þz þ
R: rejected because 1) only provided baseline data, 2) saline not used as control, 3) failed to provide all necessary WOMAC data or 4) failed
to use WOMAC or Lequesne Indices. *excluded from statistical meta-analysis. yincluded in meta-analysis (for Bellamy et al. based on HA
class versus placebo analysis of pain on weight-bearing outcome measure7). zexcluded because open, single-blinded or did not use the
VAS to measure pain outcomes. hcounted as two trials.both the Pham 200350 and Russell 199253 RCTs which had
only been published as abstracts8.
Decision-makers need to determine which review ad-
dresses the clinical question most relevant to their situationby comparing patient populations, interventions, compari-
sons, outcome measures, and settings. All reviewers iden-
tiﬁed studying OA of the knee. Bellamy et al. speciﬁed types
of participants in their review7. The Dahlberg 1994 trial24, in
Table IV
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2Arrich et al.6 Bellamy et al.7 Lo et al.8 Medina et al.9 Moda
Question: What strategies were used to search the literature?
Medline, Embase, Cinahl,
Biosis, Central (inception to
April 2004); Although not
reported in publication, they
attempted to contact all
authors of studies where only
an abstract was published.
Medline (1966 through Jan
wk 1/2006), Embase (1988
throughwk 29/2003), Premed-
line (Jul 2003), Current Con-
tents (Sept 2000), Central
(2Q2003); Handsearch to
Apr 2004 of 43 specialized
journals, abstracts fromAmer-
ican College of Rheumatol-
ogy, Asia Paciﬁc League of
Associations for Rheumatol-
ogy, European League
Against Rheumatism, Interna-
tional League of Associations
for Rheumatology, Pan-Amer-
ican League of Associations
for Rheumatology, OsteoAr-
thritis Research Society Inter-
national, American Academy
of Orthopaedic Surgeons;
Reference lists of retrieved
articles; Industry contacted
requesting additional studies.
Medline (1966 through Feb
2003), Central; Handsearch
of selected rheumatic
disease journals: (1) Arthritis
& Rheumatism, The Journal
of Rheumatology, OsteoAr-
thritis and Cartilage (2)
Abstracts of American
College of Rheumatology
and OsteoArthritis Research
Society International 1986
through 2002 (3) manuscript
bibliographies that met inclu-
sion criteria; Attempted to
contact all authors whose
studies included asking for
unpublished studies.
Medline (1966 through 2004),
PubMed (1950-2004),
CINAHL (1982-2004); Hand-
search of reference lists of
all retrieved studies; Attemp-
ted to contact authors who
did not provide necessary
statistics for meta-analysis
but received no replies.
Medline (19
August 200
of reference
articles and
Cochrane L
sites of the
Healthcare
Quality; Atte
authors of
additional d
in publicatio
Question: Were there language-restricted searches?
English or German language. No language restrictions. English and non-English. English language only. English lang
Question: Were unpublished studies included?
Yes: Russell53. Abstracts not
included.
Yes: Hizmetli35, Moreland47,
Lin45. Abstracts included:
Cohen20, Groppa32, Guler33,
Tsai60.
Yes: Pham50 and Russell53.
Abstracts included: Cohen20,
Pham50, and Russell53.
No. Abstracts not included. No. Abstrac
Question: What were the trial inclusion criteria?
RCT, HA compared with
placebo in patients with OA
RCT single- or double-blind,
HA compared with placebo; at
least one of 4 OMERACT III
core set outcome measures64
RCT single- or double-blind,
HA at least every 3 wk
compared with intra-articular
placebo. Pain had to be
assessed and reported using
one of hierarchy (Osteo
Arthritis Research Society
International) Minimum follow-
up time of 2 months and drop-
out rate of less than 50%
RCT that included a control
group that used placebo
saline injections. Means and
standard deviations had to
be provided at baseline for
the WOMAC OA Index or
Lequesne.
RCT double
compared w
Pain using
excluded W
pain VAS.
Question: Was methodological quality assessed?
Sensitivity analysis com-
pleted based on allocation
concealment, blinding and
intention-to-treat analysis
5-point Jadad scale65,
assessed by 2 reviewers,
differences adjudicated by
3rd reviewer
Not formally assessed. Eval-
uated each trial for type of
analysis performed.
Physiological Evidence Data-
base (PEDro)66 rating scale
assessed by 2 reviewers in-
dependently [Personal com-
munication J. Medina]
Chalmers e
1428 J. Campbell et al.: Differences between systematic reviews of hyaluronic acid in OAwhich it was reported that radiographs obtained in a stan-
dardized manner at the time of arthroscopic examination
did not show any evidence of OA based on the Ahlback
classiﬁcation criteria, was included in two reviews6,8; but
was not included in the other four reviews7,9e11. Arrich
et al. classiﬁed this trial as a high quality trial6. With respect
to interventions, the Russell 1992 trial53, in which the inter-
vention was sodium hyaluronate (Healon), a HA product not
marketed for OA of the knee, was included in two re-
views6,8. Lo et al. included trials in which intra-articular HA
was ‘‘administered at least every week for three weeks as
recommended by manufacturers’’8. A three-injection rather
than a ﬁve-injection schedule of Hyalgan was utilised in the
Bragantini 1987 RCT16. This trial was excluded in three re-
views8-10. Arrich et al. used both the 20 mg and 40 mg dose
data6 whereas Bellamy et al. and Wang et al. included only
the 20 mg dose data7,11. The Bunyaratavej 2001 trial18 was
not included in four reviews8e11 . A four-injection schedule
of Hyalgan was used in this trial. The Grecomoro 1987
trial30 was included in four reviews but Lo et al. and Medina
et al. excluded it8,9. A three-injection schedule of Hyalgan
was used in this trial.
The Modawal et al. review included only double-blind
RCT10, while the other ﬁve reviews included both single-
and double-blind RCT6e8,11. Modawal et al. did not include
the single-blind Dougados 199327 trial10; whereas it was in-
cluded in the other ﬁve reviews (Table IV).
Bellamy et al.7 and Wang et al.11 included the Dickson
2001 RCT26 in which arthrocentesis and placebo capsules
served as the control group; the other reviews did not in-
clude this RCT. Bellamy et al. included the Neustadt 2005
RCT48 which was an arthrocentesis-controlled trial7.
Even if a trial was selected for inclusion, differences oc-
curred as to which data were extracted (Table V). In
some reviews authors reported that data could not be
used for analysis or were not reported, while in other re-
views authors did analyse and report data for the same tri-
als. Data sources varied among the reviews with some
reviewers using additional data provided by trial authors,
industry or the United States Food and Drug Administration
Pre-Market Approval reports. For example, for the Russell
1992 RCT53, Arrich et al. received a full text article6 while
Lo et al. received data8. Lo et al. reported that details of
the results of this trial were provided by the ﬁrst author8.
However, they did not report an effect size for this trial as
the data were unpublished, and they excluded it from the
analysis evaluating publication bias. This trial was not
included in the other four reviews7,9-11. Arrich et al. did
not include the Creamer 1994 trial22 citing that observations
may not have been independent with the patient’s other
knee serving as the control6.
Reviewers used different baselines for data extraction
(Table V). While the last injection was used as the time-
point of reference in two reviews7,9, the ﬁrst injection was
used in one8, baseline was used in one10, and the reference
was not clearly reported in one review6. Endpoints for fol-
low-up assessments also varied among the reviews. Similar
predeﬁned time-points were used in three reviews6,7,9. Me-
dina et al. collapsed time-points into two broad categories
using six months as the cut-point (i.e. at least 24 weeks
and up to 52 weeks)9. Wang et al. used a data transforma-
tion where the difference between the time-point and base-
line was taken into consideration11. In the Lo et al. review,
data were extracted at two to three months (eight to 12
weeks) after the ﬁrst injection8. In the case where these
data were not available, data at one to four months (four
to sixteen weeks) after the ﬁrst injection were utilised. Forthe one-month time-point, this would reﬂect the end of treat-
ment for Hyalgan given on a ﬁve-injection weekly schedule;
whereas for Hylan G-F 20 and Orthovisc, which both utilise
a three-injection weekly schedule, this would reﬂect two
weeks after the last injection.
Both change8e10 and ﬁnal6-8 scores have been reported in
the reviews (Table V). The time interval between two time-
points was factored into the equation utilised byWanget al.11.
Although reviewers extracted different outcome mea-
sures, all reviewers included an outcome measure based
on pain6e11 but not function10 (Table V). Arrich et al. utilised
a selection algorithm to categorize end points into 12 cate-
gories but chose to analyse only the four most relevant from
a clinical perspective6. Lo et al. only included RCT that had
data on pain reported by one of the outcome measures rec-
ommended by the Osteoarthritis Research Society Interna-
tional8. In their hierarchy global knee pain was at the top.
Arrich et al. relegated this outcome to one of the eight
non-analysed categories. Bellamy et al. had planned to
use a hierarchy of outcome measures including the out-
come measures for arthritis clinical trials (OMERACT)
core set64, but in their review reported a variable-by-vari-
able extraction7. Medina et al. restricted inclusion to those
trials which utilised either the Western Ontario and McMas-
ter Universities (WOMAC) Osteoarthritis Index or the Le-
quesne Index9. Modawal et al. included pain reported on
a visual analogue scale; however, they excluded RCTs re-
porting VAS as part of the WOMAC Osteoarthritis Index
scale10. Wang et al. categorised pain intensity into pain
with activities and pain without activities11.
Data based on patients was reported in some reviews
while data based on knees was reported in others. It was
not always apparent if these data were combined in analy-
ses in some reviews. Data based on individual patients
were not reported in any of the reviews.
Methods of imputing missing data varied among the re-
views. In cases where an estimate of the variance was
not reported, the following methods were utilised to esti-
mate the variance: estimated from ﬁgures using Microsoft
photo editor converting the pixels into the units on the scale
of the graph to estimate the data points on the ﬁgure7, cal-
culated standard deviation (SD) from p values or conﬁdence
intervals6, used median for mean6,7, and if range given then
SD calculated as range divided by four7, or if inter-quartile
range given converted into SD6, imputed SD using median
coefﬁcient of variation from similar trials8, imputed standard
error using the method of Follman et al.9, and imputed SD
by multiplying the mean for the trial arm by the median co-
efﬁcient of variation from other included arms that used the
same category of outcome10. Medina et al. set, as a trial in-
clusion criterion that both means and standard deviations
had to be provided9.
Different summary statistics were reported in the six re-
views: effect size based on standardised mean difference
(SMD) using Cohen’s frame of reference8, weighted mean
difference6,7, mean difference9e11 and un-standardised
mean difference11 for continuous outcome measures, rela-
tive risk for dichotomous outcome measures7,11, and risk ra-
tios to combine adverse events6 (Table V).
Although not always formally assessed, the methodolog-
ical quality of the included RCT was taken into consider-
ation in all reviews (Table IV). Four different scales were
utilised to score quality7,9e11. A high quality trial was de-
ﬁned by Arrich et al. as a trial that reported blinding, alloca-
tion concealment and used an intention-to-treat analysis6.
They completed a sensitivity analysis based on these three
attributes. Four trials fulﬁlled these criteria: Dahlberg
Arrich et al.6 dawal et al.10 Wang et al.11
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Data extraction and statistical methods for data synthesis
Bellamy et al.7 Lo et al.8 Medina et al.9 Mo
was data extracted?
using prede-
crepancies
scussion with
One reviewer
independently extracted data
using a developed
data form and a second
reviewer independently
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Two reviewers
extracted data together
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t methods of data synthesis were used?
Modawal et al.10 Wang et al.11
a
d an
.
MDs of change
from baseline, if SE not
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et al.; Der Simonian and
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estimates.
Efﬁcacy: METAN programme
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Safety: METAN programme
methods of Mantel-Haenszel
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95% CI; Subgroup analyses
of 23 categorical attributes;
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Arrich et al.6 Bellamy et al.7 Lo et al.8 Medina et al.9
Continuous outcome
measures: WMD/SMD
and 95% CI; summary
risk ratios to combine
adverse events and 95% CI;
sensitivity analyses for
allocation concealment,
blinding, intention-to-treat
separately and for RCT that
met all 3 criteria and for MW
(900 kDa and >900 kDa);
Change or ﬁnal scores?
Continuous outcome
measures: WMD/SMD and
95% CI; dichotomous
outcome measures: relative
risk and 95% CI; Unadjusted
post-test scores.
Effect size calculated for
each RCT based on SMD¼
[{painHA-painPL}/{pooledSD};
Change from
baseline, but if not available,
then ﬁnal scores used.
Data converted into a
percentage of the total
possible score for each
outcome measure using
method described by a
statistical consultant an
algorithm developed by
one of the investigators
Effect sizes were also
calculated.
Question: How was heterogeneity tested?
Cochrane’s Q test Chi-square test (p-value
 0.10RE model)
Cochrane’s Q test Not tested formally as a
reviewing data (means
standard deviations) it w
not considered necessa
reviewers [Personal
communication J. Medi
Question: Was publication bias assessed?
No No Tested by funnel plots
and Egger test.
No
Question: Which software package was used for analyses?
Unknown RevMan 4.2.8 SAS V8.2 MATLAB 7.0
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Bellamy et al. utilised the Jadad et al. scale65 to score qual-
ity7. However, no analyses, based on these scores, were
conducted. Lo et al. did not use a scale to assess quality8.
However, in their meta-analysis, they included seven trials
that provided intent-to-treat data (Table III). Medina et al. re-
ported perfect agreement for rating the quality of the trials
using the PEDro66 rating scale.9 The average score was
8.2 out of a possible10. Modawal et al.10 reported poor qual-
ity scores (<0.75) by the Chalmers et al. method67 for four
of nine trials included in their review: Grecomoro 198730,
Huskisson 199936, Scale 199454, and Wobig 199861.
They tested the inﬂuence of study quality by a random-ef-
fect regression model, and found that poor quality trials
had a larger treatment effect, the difference statistically sig-
niﬁcant at Week one. Wang et al. utilised the quality score
of the methodology in a meta-regression analysis11. This
analysis showed that trials with lower methodological qual-
ity provided higher estimates of efﬁcacy.
The ability to combine trial results (heterogeneity testing)
was assessed in all six reviews (Table V). Signiﬁcant het-
erogeneity was found among the trials. Arrich et al. did
not report a summary effect or weight the data where het-
erogeneity was statistically signiﬁcant; they only reported
a summary effect for homogeneous trials, and cautioned
readers when pooled results were presented with unex-
plained statistical heterogeneity6. Bellamy et al. focussed
on a by-product analysis rather than the HA class analysis,
and when heterogeneity was statistically signiﬁcant used
a random effects model7. Lo et al. found that, after exclud-
ing three trials that evaluated one HA product42,54,61, het-
erogeneity was not statistically signiﬁcant among the
remaining trials8. Medina et al. completed meta-analysis
based on the homogeneity of their included studies9. Mod-
awal et al. evaluated heterogeneity, found at all time-points
except Week one, with random-effect regression models to
explore three sources of heterogeneity9. Wang et al. inves-
tigated ten factors to assess heterogeneity within each sub-
group of trials11. They found no statistically signiﬁcant
between-trial heterogeneity when only the trials in which
a non-cross-linked HA were included.
Publication bias was evaluated in three of the re-
views8,10,11 (Table V). Lo et al. reported evidence of publi-
cation bias8. Modawal et al. reported no publication
bias10. Wang et al. reported that publication bias was un-
likely to have had an effect on the efﬁcacy analysis11.
Five different statistical software packages were used in
the six reviews: MATLAB 7.0, METAN, RevMan 4.2.8, SAS
V8.2, STATA, and not reported in one review (Table V). As
no between-software analyses were reported, it is unknown
whether the utilisation of these different programmes had
any inﬂuence on the results of the reviews.
The strength of the evidence was assessed using the
GRADE system in which four elements were assessed12.
The study design for all trials included in the six reviews
was randomised controlled trial which is scored as a high
type of evidence. Study quality was assessed by reviewing
whether the studies had limitations or ﬂaws. The following
limitations were noted: allocation concealment was not re-
ported or unclear, some trials were single-blind not double-
blind and frequently the method of blinding was not reported
in detail, methods of randomisation were not clearly re-
ported, incomplete descriptions of withdrawals and drop-
outs were reported, analyses were frequently based on the
per protocol or completer population not on the intention-
to-treat population, statistically signiﬁcant differences were
reported at baseline between treatment and control groups,different populations of knee OA patients were included
(i.e. unilateral versus bilateral disease, presence versus ab-
sence of effusion, radiological stage and grading schema,
age, gender balance, disease duration, baseline pain sever-
ity), different methods for assessing outcomewere used both
with respect to outcome measures and time-points. In addi-
tion, the following between study differences have been ob-
served: sample size, number of study arms, number of
centres, clinical environment (e.g. community, hospital, and
specialty (rheumatology or orthopaedic), or general practi-
tioner), nature of the placebo comparator (e.g. saline, arthro-
centesis), inclusion/exclusion criteria, washout period,
re-treatment opportunity, concomitant therapy (e.g. rescue
analgesia, physiotherapy, non-steroidal anti-inﬂammatory
drugs), follow-up schedule, duration of follow-up, and treat-
ment schedule. These differences make it difﬁcult to com-
pare the six SR. Important inconsistencies were noted in
the results of the six SR leading to some uncertainty in the
directness of the evidence. The ﬁnal recommendation
should be based on the response to the question, ‘‘Does
the intervention do more good than harm?’’ Although the
overall quality was moderate, there were net beneﬁts (pain
reduction and physical function) in favour of HA compared
to placebo with low risk of harm. Therefore, the recommen-
dation is to ‘‘probably’’ use HA.
Discussion
The six SR differed in many methodological aspects.
These differences may explain, in part, the different conclu-
sions reached by the reviewers.
Although the search strategies were similar, the utilisation
of different electronic databases may have inﬂuenced the
identiﬁcation of trials for inclusion in the reviews. Reliance
only on Medline may be inadequate68,69. Restricting inclu-
sion to trials published in only one language, most fre-
quently English, restricts the generalizability of the results.
The inclusion of unpublished work is often controversial.
Some believe that reviews should be as inclusive as possi-
ble and, therefore, recommend using all sources of data
(i.e. personal communication, in-house clinical reports, dis-
sertations)70. Others believe that only data that have gone
through the peer review process should be utilised. These
different viewpoints are reﬂected in the six reviews. Simi-
larly, some reviewers chose to include abstracts while
others chose to exclude them.
The advantage of erring on the side of over-inclusion is
that it permits the analysis of publication status as a covari-
ate. Where such status is clearly linked with effect size or
heterogeneity, more limited sub-analyses can be done
which then permit statements about the limitations on the
results that may be implied by such effects.
The data available for analysis is often dependent upon
the strategy used to obtain data not reported in the publica-
tion. Some review authors attempted to contact trial authors
directly or industry to clarify or receive further data regard-
ing trials. However, the response by trial authors and/or in-
dustry to such requests may have varied depending on
reasons for the request or from whom the request came.
When completing the analysis, reviewers need to con-
sider which comparisons to complete, which trials to com-
bine, what methods to use, and whether or not subgroup
or sensitivity analyses are warranted.
With respect to comparisons, reviewers need to deﬁne
what they consider to be an intra-articular placebo. In these
reviews, deﬁnition of a placebo is not straightforward.
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intra-articular saline or sham injection, or could it include ar-
throcentesis. In the six reviews, the Dickson 2001 double-
blind RCT26, where the control consisted of arthrocentesis
and placebo capsules, was included in two reviews. Across
the trials included in the reviews, different numbers of injec-
tions and dose of a given product were evaluated. Re-
viewers must decide if they should include all doses and
schedules or only those based on regulatory authorities ap-
proval submissions or labels.
The outcome measures which were extracted and ana-
lysed varied extensively among the reviews. Pain, function,
and limitation of activities of daily living are the most fre-
quently reported outcome measures in OA clinical trials.
In order to pool trials, it is preferable to combine trials that
measure the same outcome. Differences in scaling can be
corrected by statistical methods, e.g. SMD. However, re-
viewers need to consider if they should combine pain during
active motion (i.e. weight-bearing activities such as walking
or stair climbing) with spontaneous pain or pain during rest
(i.e. non-weight-bearing activities such as night pain). In
one review, pain was analysed separately for pain with ac-
tivities and pain without activities. In one review, where a hi-
erarchy of pain outcome measures was utilised, the ﬁrst
outcome in that hierarchy, global pain, was not analysed
in another review. The same dilemma holds for function out-
come measures; reviewers need to decide if one function
measure should be selected in preference to another. While
some decision-makers may be familiar with disease-spe-
ciﬁc functional outcome measures such as the WOMAC
OA Index or the Lequesne Index, other decision-makers
may place importance on more objective outcome mea-
sures such as walking time, walking distance or range of
motion. On the other hand, one could argue that the pre-
ferred outcome measure for data extraction should be the
primary outcome measure on which presumably the statis-
tical power of the trial was based71.
The time-points selected for data extraction varied among
the six reviews. The effect of mixing time frames is unknown
particularly when different dosage schedules are utilised by
different products. It is important to recognize that due to the
upward, then downward slopes of a typical dose-response
curve that the exact timing of follow-ups is a likely factor
in determining effect size. The narrowing of the band of
time may reduce heterogeneity, but it will restrict
understanding of the nature of the response, which is an
important clinical element. Conversely, the widening of
the band requires more than a simple analysis that pro-
vides a single summary statistic, because observed het-
erogeneity is likely to follow a nonlinear pattern with
respect to the exact timing of outcome measurements.
Human error, both random and systematic, can occur
during the data extraction procedure72. However, with
data extraction completed by two reviewers or veriﬁed inde-
pendently the likelihood of this occurring can be minimised.
Kappas or other such measures would be valuable addi-
tions to the meta-analytic armamentarium to ensure inter-
extractor agreement.
Often results are reported as ﬁgures in publications.
When only graphical results are presented there are a num-
ber of methods for estimating the numbers (e.g. cross-hair
facility of Photo-Finish). An element of error is associated
with any of these methods. Once again, multiple extractions
could permit some estimate of the extent of this variability,
and strategies (e.g. taking the worst case scenario) could
be developed to appreciate the inﬂuence of this factor on
meta-analytic outcomes.Should the analysis be based on the joint or the person?
Does mixing the unit of measurement affect the results?
These questions have been addressed in two publica-
tions73,74. Data were reported both at the level of the joint
and the patient in the reviews. We note that where analy-
ses treat correlated data as if they were from independent
groups, the covariance is not subtracted from the error
term, which results in a conservative estimate for the study
in question. Where this practice is widespread in a body of
research, the degree to which this leads to underestima-
tion of effect sizes is in itself an interesting empirical
question.
There are several approaches to measuring treatment ef-
fects75e83: 1) mean outcome scores at follow-up, 2) mean
change from baseline, 3) percent change from baseline,
and 4) meta-regression analysis adjusting for baseline
scores.84 Often pooled standard deviations are used, al-
though sometimes only the baseline control group standard
deviation may be used. Whether change scores or endpoint
scores82 (i.e. ﬁnal measurements) should be used for data
extraction is undecided. In the Cochrane handbook ‘‘re-
viewers are advised not to focus on change from baseline
unless this method of analysis was used in some of the trial
reports’’75. The handbook recommends that ‘‘ﬁnal value and
change scores should not be combined together as SMD,
since the difference in SD reﬂects not differences in
measurement scale, but differences in the reliability of the
measurements’’75. Vickers and Altman presented an exam-
ple of analysing data with baseline and follow-up measure-
ments77. For a reported pain score, P values were: 0.0008
for the follow up or post-treatment score, 0.014 for the
change score, and 0.005 for the analysis of covariance.
Therefore, the choice of which method is used may affect
the level of statistical signiﬁcance, and we suggest that fur-
ther research continue into the differences that the various
approaches may create given the same data.
Often publications do not report the standard deviation of
the change scores. Similarly, measures of dispersion (stan-
dard deviation, standard error) were frequently not reported
in the publications. Consequently, estimates of the variance
were imputed using different strategies. There are methods
for imputing SD but reviewers are cautioned that, ‘‘all impu-
tation techniques involve making assumptions about un-
known statistics, and it is best to avoid using them
wherever possible’’75.
To summarise the impact of treatment across the trials,
several summary statistics were utilised in the reviews85.
Zou has recently examined the conceptual differences be-
tween Cohen’s effect size and the SRM in quality of life
measures86. He showed that only the SRM is necessary
to quantify responsiveness. Blanchard et al. used ﬁve
responsiveness statistics to examine the responsiveness
of both disease-speciﬁc and generic outcome measures in
OA patients undergoing total hip replacement87. The ﬁve
statistics they studied were: 1) the paired t-test, 2) ES using
the baseline SD in the denominator, 3) Guyatt’s statistic
with a modiﬁcation using the square root of two times the
mean square error in the denominator, and 4) standardised
response mean which has the change SD in the denomina-
tor. For the WOMAC OA Index pain subscale, the respon-
siveness statistic was reported as: 1) 2.72, 2) 2.37, 3)
6.69, and 4) 22.47, respectively. From this example, it is
evident that the magnitude of the summary statistic is de-
pendent upon the method used to express it.
Lo et al. suggested that the ES of the Scale trial (1.76)54
and Wobig trial (1.55)61 did not seem realistic8. These ES
may have been interpreted differently if a different
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replacement. Lo et al.8 reported a total knee replacement
as having an ES of 1.088,89. However, estimates of the ef-
fect size/SRM of total knee replacement reported in the lit-
erature for WOMAC OA Index pain have ranged from 0.45
to 4.8990e98. It is evident from these examples that there
exists a wide range of potential values for the summary
statistic.
Although trial quality was assessed in all six reviews, not
all of them incorporated the results in the subsequent analy-
ses. This trend was noted in an analysis of systematic re-
views in Issue 2, 2003 of the Cochrane Database of
Systematic Reviews where half of the reviews did not incor-
porate the results of the quality assessment in the analysis99.
There was signiﬁcant heterogeneity among the trials in-
cluded in these reviews. As noted in the Results section
many between-trial differences were noted. There are differ-
ent methods of dealing with heterogeneity: 1) do not pool at
all, 2) ignore and use a ﬁxed effects model assuming that tri-
als are estimating the same unknown treatment effect, 3) use
a random effects model assuming that trials are estimating
different, but related, unknown treatment effects with the dif-
ferences between these represented by random variation,
and 4) explore with subgroup analysis and meta-regression.
Although publication bias was assessed in three of the re-
views, conﬂicting results were reported. Terrin, Schmid and
Lau have suggested that the asymmetry in funnel plots
may be due to chance or heterogeneity, and they caution
interpreting it as publication bias100,101.
Although we have used the GRADE approach to rate
the quality of the evidence and the strength of the recom-
mendation, it is important to remember that the need for
judgement is still required. It may seem that this paper
questions the traditional hierarchy of levels of evidence
by drawing attention to the inﬂuence of methodology on
the results of SR and meta-analyses. To the contrary,
good quality SR can be an invaluable source of evidence
for clinical decision-makers. It should be noted, given that
practitioners treat patients at an individual level, that prod-
uct-level SR are much more informative to clinicians than
class-level analyses7, since they can more directly sup-
port clinical decision-making. Readers of HA class-level
SR need to be aware that methodological differences
occur in these reviews, which may impact on the results
and that they must assess qualitative aspects of SR in or-
der to understand why they may conﬂict with each other,
or contrast with product level SR, or with the results of
individual randomised trials.
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